KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).PMID 40306120 · 2025-Jun-03eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.PMID 39322611 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.PMID 39743478 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.PMID 39818468 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.PMID 39884884 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.PMID 40097073 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.PMID 40099663 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.PMID 40140172 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.PMID 40204616 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.PMID 40217078 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.PMID 40286809 · 2025-Juneligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.PMID 40300278 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.PMID 40349716 · 2025-Juneligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.PMID 40449498 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.PMID 40528576 · 2025-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.PMID 40437469 · 2025-May-28eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.PMID 40349714 · 2025-May-24eligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).PMID 40048691 · 2025-May-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.PMID 40193822 · 2025-May-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.PMID 40262400 · 2025-May-15eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.PMID 40079940 · 2025-May-13eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.PMID 40079944 · 2025-May-13eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.PMID 40360463 · 2025-May-13eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.PMID 40350200 · 2025-May-11needs_reviewThe record is a randomized, phase III trial of a drug (upadacitinib) in a human, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the core oncology criterion.pending-The record is a randomized, phase III trial of a drug (upadacitinib) in a human, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the core oncology criterion.
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.PMID 39854662 · 2025-May-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.PMID 40043230 · 2025-May-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.PMID 40346047 · 2025-May-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.PMID 39652675 · 2025-May-08eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.PMID 40328753 · 2025-May-07eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial.PMID 40121836 · 2025-May-02eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.PMID 40139004 · 2025-May-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.PMID 39656951 · 2025-May-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.PMID 39772884 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.PMID 39777934 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.PMID 39814199 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit.PMID 39863112 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.PMID 39879577 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses.PMID 39924128 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.PMID 39934055 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.PMID 40044930 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.PMID 40220771 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.PMID 40250457 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.PMID 40261119 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.PMID 40306831 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).PMID 40403198 · 2025-Mayeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.PMID 40441802 · 2025-Mayneeds_reviewThe abstract reports a randomized phase III trial with a drug intervention, but the primary/key secondary efficacy endpoint is patient-reported outcomes (quality of life), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report is therefore excluded as a quality-of-life analysis.pending-The abstract reports a randomized phase III trial with a drug intervention, but the primary/key secondary efficacy endpoint is patient-reported outcomes (quality of life), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report is therefore excluded as a quality-of-life analysis.
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.PMID 39778121 · 2025-Apr-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.PMID 39992668 · 2025-Apr-15eligible命中用户提供的消化道肿瘤阳性参考集。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial.PMID 40008901 · 2025-Apr-14eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.PMID 39746176 · 2025-Apr-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。